Overexpression of miR-382 Sensitizes Hepatocellular Carcinoma Cells to γδ T Cells through Inhibiting the Expression of C-Flip

As miR-382 was observed to be downregulated in hepatocellular carcinoma (HCC) tissues and cell lines, researchers found that overexpression of miR-382 increased the sensitivity of HCC cells to γδ T cells.
[Molecular Therapy-Oncolytics]
Chen, Z., Zheng, Z., Feng, L., Huo, Z., Huang, L., Fu, M., Chen, Q., Ke, Y., Yang, J., & Hou, B. (2020). Overexpression of miR-382 sensitizes hepatocellular carcinoma cells to γδ T cells through inhibiting the expression of c-FLIP. Molecular Therapy - Oncolytics, 0(0). https://doi.org/10.1016/j.omto.2020.07.012 Cite
AbstractGraphical Abstract

Continue reading “Overexpression of miR-382 Sensitizes Hepatocellular Carcinoma Cells to γδ T Cells through Inhibiting the Expression of C-Flip”

Bookmark

No account yet? Register

0
Share

A Large-Scale Binding and Functional Map of Human RNA-Binding Proteins

Scientists describe the mapping and characterization of RNA elements recognized by a large collection of human RNA-binding proteins in K562 and HepG2 cells.
[Nature]
Van Nostrand, E. L., Freese, P., Pratt, G. A., Wang, X., Wei, X., Xiao, R., Blue, S. M., Chen, J.-Y., Cody, N. A. L., Dominguez, D., Olson, S., Sundararaman, B., Zhan, L., Bazile, C., Bouvrette, L. P. B., Bergalet, J., Duff, M. O., Garcia, K. E., Gelboin-Burkhart, C., … Yeo, G. W. (2020). A large-scale binding and functional map of human RNA-binding proteins. Nature, 583(7818), 711–719. https://doi.org/10.1038/s41586-020-2077-3 Cite
Full Article

Continue reading “A Large-Scale Binding and Functional Map of Human RNA-Binding Proteins”

Bookmark

No account yet? Register

0
Share

Fatty Acid Mimetic PBI-4547 Restores Metabolic Homeostasis via GPR84 in Mice with Non-Alcoholic Fatty Liver Disease

The authors evaluated the potential of PBI-4547 for the treatment of non-alcoholic fatty liver disease and to validate the role of its main target receptor, G protein-coupled receptor 84 (GPR84).
[Scientific Reports]
Simard, J.-C., Thibodeau, J.-F., Leduc, M., Tremblay, M., Laverdure, A., Sarra-Bournet, F., Gagnon, W., Ouboudinar, J., Gervais, L., Felton, A., Letourneau, S., Geerts, L., Cloutier, M.-P., Hince, K., Corpuz, R., Blais, A., Quintela, V. M., Duceppe, J.-S., Abbott, S. D., … Gagnon, L. (2020). Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease. Scientific Reports, 10(1), 12778. https://doi.org/10.1038/s41598-020-69675-8 Cite
Full Article

Continue reading “Fatty Acid Mimetic PBI-4547 Restores Metabolic Homeostasis via GPR84 in Mice with Non-Alcoholic Fatty Liver Disease”

Bookmark

No account yet? Register

0
Share

Toll-Like Receptor Dual-Acting Agonists Are Potent Inducers of PBMC-Produced Cytokines That Inhibit Hepatitis B Virus Production in Primary Human Hepatocytes

Researchers found that conditioned media (CM) from peripheral blood mononuclear cells (PBMCs) stimulated with dual-acting TLR7/8 and TLR2/7 agonists were more potent drivers of inhibition of hepatisis e and hepatitis s antigen secretion from hepatitis B virus-infected primary human hepatocytes than CM from PBMCs stimulated with single-acting TLR7 or TLR9 agonists.
[Scientific Reports]
Janovec, V., Hodek, J., Clarova, K., Hofman, T., Dostalik, P., Fronek, J., Chlupac, J., Chaperot, L., Durand, S., Baumert, T. F., Pichova, I., Lubyova, B., Hirsch, I., & Weber, J. (2020). Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes. Scientific Reports, 10(1), 12767. https://doi.org/10.1038/s41598-020-69614-7 Cite
Full Article

Continue reading “Toll-Like Receptor Dual-Acting Agonists Are Potent Inducers of PBMC-Produced Cytokines That Inhibit Hepatitis B Virus Production in Primary Human Hepatocytes”

Bookmark

No account yet? Register

0
Share

microRNA-93-5p Promotes Hepatocellular Carcinoma Progression via a microRNA-93-5p/MAP3K2/C-Jun Positive Feedback Circuit

miR-93-5p expression was assessed in hepatocellular carcinoma (HCC) tissues and cell lines by quantitative real-time PCR and fluorescence in situ hybridization. The correlation of miR-93-5p expression with survival and clinicopathological features of HCC was determined by statistical analysis.
[Oncogene]
Shi, X., Liu, T.-T., Yu, X.-N., Balakrishnan, A., Zhu, H.-R., Guo, H.-Y., Zhang, G.-C., Bilegsaikhan, E., Sun, J.-L., Song, G.-Q., Weng, S.-Q., Dong, L., Ott, M., Zhu, J.-M., & Shen, X.-Z. (2020). microRNA-93-5p promotes hepatocellular carcinoma progression via a microRNA-93-5p/MAP3K2/c-Jun positive feedback circuit. Oncogene, 1–14. https://doi.org/10.1038/s41388-020-01401-0 Cite
Abstract

Continue reading “microRNA-93-5p Promotes Hepatocellular Carcinoma Progression via a microRNA-93-5p/MAP3K2/C-Jun Positive Feedback Circuit”

Bookmark

No account yet? Register

0
Share

AMPK Activator C24 Inhibits Hepatic Lipogenesis and Ameliorates Dyslipidemia in HFHC Diet-Induced Animal Models

Researchers showed that C24 dose-dependently increased the phosphorylation of AMPKα and acetyl-CoA carboxylase, and inhibited lipogenesis in HepG2 cells.
[Acta Pharmacologica Sinica]
Sun, S., Xie, Z., Zhang, Y., Zhang, X., Zhou, C., Yin, J., Yu, Y., Cui, S., Jiang, H., Li, T., Li, J., Nan, F., & Li, J. (2020). AMPK activator C24 inhibits hepatic lipogenesis and ameliorates dyslipidemia in HFHC diet-induced animal models. Acta Pharmacologica Sinica, 1–8. https://doi.org/10.1038/s41401-020-0472-9 Cite
Abstract

Continue reading “AMPK Activator C24 Inhibits Hepatic Lipogenesis and Ameliorates Dyslipidemia in HFHC Diet-Induced Animal Models”

Bookmark

No account yet? Register

0
Share

Emerging Role of FBXO22 in Carcinogenesis

Scientists summarize the regulatory factors and downstream targets of F-box protein 22 (FBXO22) in cancers, discuss its functions in tumorigenesis, and further highlight the alteration of FBXO22 expression in a variety of human malignancies.
[Cell Death Discovery]
Cheng, J., Lin, M., Chu, M., Gong, L., Bi, Y., & Zhao, Y. (2020). Emerging role of FBXO22 in carcinogenesis. Cell Death Discovery, 6(1), 1–7. https://doi.org/10.1038/s41420-020-00303-0 Cite
Full Article

Continue reading “Emerging Role of FBXO22 in Carcinogenesis”

Bookmark

No account yet? Register

0
Share

Regulation of MYO18B mRNA by a Network of C19MC miRNA-520G, Ifn-γ, Cebpb, p53 and bFGF in Hepatocellular Carcinoma

Researchers identified a network of positive and negative regulators of MYO18B mRNA expression which reflects the survival of hepatocellular carcinoma patients.
[Scientific Reports]
Jinesh, G. G., Napoli, M., Ackerman, H. D., Raulji, P. M., Montey, N., Flores, E. R., & Brohl, A. S. (2020). Regulation of MYO18B mRNA by a network of C19MC miRNA-520G, IFN-γ, CEBPB, p53 and bFGF in hepatocellular carcinoma. Scientific Reports, 10(1), 12371. https://doi.org/10.1038/s41598-020-69179-5 Cite
Full Article

Continue reading “Regulation of MYO18B mRNA by a Network of C19MC miRNA-520G, Ifn-γ, Cebpb, p53 and bFGF in Hepatocellular Carcinoma”

Bookmark

No account yet? Register

0
Share

Anlotinib Suppresses Tumor Progression via Blocking the VEGFR2/PI3K/Akt Cascade in Intrahepatic Cholangiocarcinoma

Using in vitro experiments, investigators found that anlotinib had significant effects on proliferation inhibition, migration and invasion restraint, and cell-cycle arrestment in intrahepatic cholangiocarcinoma.
[Cell Death & Disease]
Song, F., Hu, B., Cheng, J.-W., Sun, Y.-F., Zhou, K.-Q., Wang, P.-X., Guo, W., Zhou, J., Fan, J., Chen, Z., & Yang, X.-R. (2020). Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death & Disease, 11(7), 1–14. https://doi.org/10.1038/s41419-020-02749-7 Cite
Full Article

Continue reading “Anlotinib Suppresses Tumor Progression via Blocking the VEGFR2/PI3K/Akt Cascade in Intrahepatic Cholangiocarcinoma”

Bookmark

No account yet? Register

0
Share

NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes

The authors focus on the clinical and pathophysiological connections between non-alcoholic fatty liver disease (NAFLD), insulin resistance and type 2 diabetes.
[Diabetology & Metabolic Syndrome]
NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. (n.d.). Retrieved July 24, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359287/ Cite
Full Article

Continue reading “NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes”

Bookmark

No account yet? Register

0
Share

Terns Pharmaceuticals Announces Initiation of Patient Dosing in the LIFT Study, a Phase IIa Clinical Trial of TERN-101 in Development for NASH

Terns Pharmaceuticals, Inc., has announced that it has dosed the first patient in the LIFT study, a Phase IIa clinical trial of TERN-101, a liver-selective farnesoid X receptor agonist, the company’s lead development candidate for the treatment of non-alcoholic steatohepatitis (NASH).
[Terns Pharmaceuticals]
Press Release

Continue reading “Terns Pharmaceuticals Announces Initiation of Patient Dosing in the LIFT Study, a Phase IIa Clinical Trial of TERN-101 in Development for NASH”

Bookmark

No account yet? Register

0
Share

French Science Bill Promises Boost to Public R&D

The French government this week unveiled a draft science bill that promises to increase public research spending with an extra €25 billion over the next ten years.
[ScienceInsider]
Press Release

Continue reading “French Science Bill Promises Boost to Public R&D”

Bookmark

No account yet? Register

0
Share
Share